Histopathology and clinical course of MOG-antibody-associated encephalomyelitis

Melania Spadaro(Ludwig-Maximilians-Universität München), Lisa Ann Gerdes(Ludwig-Maximilians-Universität München), Marie Cathrin Mayer(Ludwig-Maximilians-Universität München), Birgit Ertl‐Wagner(Ludwig-Maximilians-Universität München), Sarah Laurent(Ludwig-Maximilians-Universität München), Markus Krumbholz(Ludwig-Maximilians-Universität München), Constanze Breithaupt(Martin Luther University Halle-Wittenberg), Tobias Högen(Ludwig-Maximilians-Universität München), Andreas Straube(Ludwig-Maximilians-Universität München), Armin Giese(Ludwig-Maximilians-Universität München), Reinhard Hohlfeld(Ludwig-Maximilians-Universität München), Hans Lassmann(Institute of Neuroimmunology of the Slovak Academy of Sciences), Edgar Meinl(Ludwig-Maximilians-Universität München), Tania Kümpfel(Ludwig-Maximilians-Universität München)
Annals of Clinical and Translational Neurology
January 14, 2015
Cited by 176Open Access
Full Text

Abstract

We present histological, MRI, and clinical features of an adult patient with relapsing encephalomyelitis and antibodies against myelin oligodendrocyte glycoprotein (MOG). Furthermore, we report molecular details of the recognized epitope that is specific for human MOG. A brain biopsy revealed multiple sclerosis (MS)-type II pathology. Some features overlapped with both MS and neuromyelitis optica spectrum disorders (NMOSD), whereas others were distinct from both MS and NMOSD. Immunoadsorption and rituximab induced clinical stabilization. This case contributes a new, so far missing link in the emerging spectrum of MOG-antibody-associated encephalomyelitis.


Related Papers